BMS-986126

BMS-986126 is a potent, selective, and orally active IRAK4 inhibitor (IC50 = 5.3 nM) . BMS-986126 broadly inhibits MyD88-dependent signaling pathways. BMS-986126 demonstrates robust activity in the MRL/lpr and NZB/NZW murine models of lupus, inhibiting multiple pathogenic responses. BMS-986126 can be used for autoimmune diseases research, such as lupus erythematosus (SLE) [1].

Product Specifications

CAS Number

[1610017-20-3]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

ERK; Interleukin Related; IRAK; NF-κB; Toll-like Receptor (TLR)

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt

Field of Research

Inflammation/Immunology

Solubility

10 mM in DMSO

Smiles

CC(C)(O)[C@H](F)CNC(C(C(NC1CC1)=C2)=CN=C2NC3=NC4=C(C=NC=C4)C=C3)=O

Molecular Formula

C22H25FN6O2

Molecular Weight

424.47

Precautions

P261-P280-P302+P352

References & Citations

[1]Shailesh Dudhgaonkar, et al. Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity. J Immunol. 2017 Feb 1;198 (3) :1308-1319.